MX370061B - Uso de antagonistas del par-1 para prevenir y/o tratar condiciones patologicas funcionales pelviperineales. - Google Patents
Uso de antagonistas del par-1 para prevenir y/o tratar condiciones patologicas funcionales pelviperineales.Info
- Publication number
- MX370061B MX370061B MX2016007795A MX2016007795A MX370061B MX 370061 B MX370061 B MX 370061B MX 2016007795 A MX2016007795 A MX 2016007795A MX 2016007795 A MX2016007795 A MX 2016007795A MX 370061 B MX370061 B MX 370061B
- Authority
- MX
- Mexico
- Prior art keywords
- pelvi
- treating
- preventing
- antagonists
- pathological conditions
- Prior art date
Links
- 229940098892 Protease-activated receptor-1 antagonist Drugs 0.000 title abstract 2
- 230000001575 pathological effect Effects 0.000 title abstract 2
- KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 abstract 1
- QWKAUGRRIXBIPO-UHFFFAOYSA-N Atopaxar Chemical compound N=C1C=2C(F)=C(OCC)C(OCC)=CC=2CN1CC(=O)C(C=C(C=1OC)C(C)(C)C)=CC=1N1CCOCC1 QWKAUGRRIXBIPO-UHFFFAOYSA-N 0.000 abstract 1
- 208000005615 Interstitial Cystitis Diseases 0.000 abstract 1
- 229950007648 atopaxar Drugs 0.000 abstract 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229960005044 vorapaxar Drugs 0.000 abstract 1
- ZBGXUVOIWDMMJE-QHNZEKIYSA-N vorapaxar Chemical compound C(/[C@@H]1[C@H]2[C@H](C(O[C@@H]2C)=O)C[C@H]2[C@H]1CC[C@H](C2)NC(=O)OCC)=C\C(N=C1)=CC=C1C1=CC=CC(F)=C1 ZBGXUVOIWDMMJE-QHNZEKIYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
La presente invención se refiere al uso de antagonistas del PAR1, en particular de vorapaxar, de atopaxar y de 3- (2-cloro-fenil) -1- [4- (4-fluoro-bencil)piperazin-1-il] propenona, o una sal farmacéuticamente aceptable sal de los mismos, para prevenir y/o tratar condiciones patológicas funcionales pelviperineales y, más particularmente, el síndrome de vejiga dolorosa.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1362682A FR3014693B1 (fr) | 2013-12-16 | 2013-12-16 | Utilisation de la 3-(2-chloro-phenyl)-1-[4-(4-fluoro-benzyl)-piperazin-1-yl]-propenone pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales |
PCT/EP2014/073453 WO2015090705A1 (fr) | 2013-12-16 | 2014-10-31 | Utilisation d'antagonistes par-1 pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2016007795A MX2016007795A (es) | 2016-09-07 |
MX370061B true MX370061B (es) | 2019-11-29 |
Family
ID=50424483
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016007795A MX370061B (es) | 2013-12-16 | 2014-10-31 | Uso de antagonistas del par-1 para prevenir y/o tratar condiciones patologicas funcionales pelviperineales. |
Country Status (17)
Country | Link |
---|---|
US (2) | US9980970B2 (es) |
EP (1) | EP3082818A1 (es) |
JP (1) | JP6612233B2 (es) |
KR (1) | KR20160089518A (es) |
CN (1) | CN105813642B (es) |
AU (1) | AU2014365665B2 (es) |
CA (1) | CA2931161A1 (es) |
FR (1) | FR3014693B1 (es) |
HK (1) | HK1221913A1 (es) |
IL (1) | IL246216A0 (es) |
MA (1) | MA39072A1 (es) |
MX (1) | MX370061B (es) |
RU (1) | RU2678309C1 (es) |
SA (1) | SA516371348B1 (es) |
TN (1) | TN2016000196A1 (es) |
UA (1) | UA120603C2 (es) |
WO (1) | WO2015090705A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3090317B1 (fr) * | 2018-12-19 | 2021-05-07 | Cvasthera | Utilisation d’un antagoniste de par-1 pour le traitement d’une maladie inflammatoire chronique intestinale |
CN110393718B (zh) * | 2019-08-20 | 2022-10-04 | 青岛海洋生物医药研究院 | 阿托帕沙溴酸作为新型jak-stat3信号通路抑制剂的用途和研究方法 |
FR3109089B1 (fr) * | 2020-04-08 | 2023-04-14 | Cvasthera | Composition pharmaceutique pour le traitement des maladies inflammatoires intestinales |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1495018E (pt) | 2002-04-16 | 2008-02-19 | Schering Corp | Antagonistas tricíclicos de receptores de trombina |
EP2380904A1 (en) * | 2004-11-04 | 2011-10-26 | Tufts Medical Center, Inc. | G protein coupled receptor agonists and antagonists and methods of use |
FR2902426B1 (fr) * | 2006-06-19 | 2008-09-05 | Pierre Fabre Medicament Sa | Derives de cinnamoyl-piperazine |
CA2834621A1 (en) * | 2011-05-12 | 2012-11-15 | Universite Laval | Par1 inhibitors for use in the treatment or prevention of paramyxoviridae infections |
RU2468759C1 (ru) * | 2011-09-23 | 2012-12-10 | Ольга Викторовна Тарабанова | Способ лечения нарушений анатомических соотношений органов малого таза у женщин с атрофией мышц, поднимающих задний проход, и/или множественными дефектами ректо-вагинальной фасции |
-
2013
- 2013-12-16 FR FR1362682A patent/FR3014693B1/fr not_active Expired - Fee Related
-
2014
- 2014-10-31 WO PCT/EP2014/073453 patent/WO2015090705A1/fr active Application Filing
- 2014-10-31 US US15/101,170 patent/US9980970B2/en not_active Expired - Fee Related
- 2014-10-31 MX MX2016007795A patent/MX370061B/es active IP Right Grant
- 2014-10-31 TN TN2016000196A patent/TN2016000196A1/fr unknown
- 2014-10-31 MA MA39072A patent/MA39072A1/fr unknown
- 2014-10-31 KR KR1020167017262A patent/KR20160089518A/ko not_active Application Discontinuation
- 2014-10-31 CN CN201480068095.9A patent/CN105813642B/zh not_active Expired - Fee Related
- 2014-10-31 UA UAA201607312A patent/UA120603C2/uk unknown
- 2014-10-31 EP EP14793086.1A patent/EP3082818A1/fr not_active Withdrawn
- 2014-10-31 RU RU2016127158A patent/RU2678309C1/ru not_active IP Right Cessation
- 2014-10-31 AU AU2014365665A patent/AU2014365665B2/en not_active Ceased
- 2014-10-31 CA CA2931161A patent/CA2931161A1/fr not_active Abandoned
- 2014-10-31 JP JP2016540042A patent/JP6612233B2/ja not_active Expired - Fee Related
-
2016
- 2016-06-14 IL IL246216A patent/IL246216A0/en unknown
- 2016-06-16 SA SA516371348A patent/SA516371348B1/ar unknown
- 2016-08-25 HK HK16110155.2A patent/HK1221913A1/zh not_active IP Right Cessation
-
2018
- 2018-04-25 US US15/962,837 patent/US10265322B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN105813642A (zh) | 2016-07-27 |
FR3014693A1 (fr) | 2015-06-19 |
SA516371348B1 (ar) | 2019-11-10 |
CN105813642B (zh) | 2019-05-03 |
KR20160089518A (ko) | 2016-07-27 |
UA120603C2 (uk) | 2020-01-10 |
AU2014365665A1 (en) | 2016-07-14 |
WO2015090705A1 (fr) | 2015-06-25 |
IL246216A0 (en) | 2016-07-31 |
AU2014365665B2 (en) | 2019-08-29 |
RU2678309C1 (ru) | 2019-01-25 |
JP2016540799A (ja) | 2016-12-28 |
HK1221913A1 (zh) | 2017-06-16 |
MA39072A1 (fr) | 2017-05-31 |
US20180311253A1 (en) | 2018-11-01 |
EP3082818A1 (fr) | 2016-10-26 |
CA2931161A1 (fr) | 2015-06-25 |
MX2016007795A (es) | 2016-09-07 |
TN2016000196A1 (fr) | 2017-10-06 |
FR3014693B1 (fr) | 2016-01-08 |
US20160287603A1 (en) | 2016-10-06 |
JP6612233B2 (ja) | 2019-11-27 |
US9980970B2 (en) | 2018-05-29 |
US10265322B2 (en) | 2019-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL260297A (en) | Process for preparing n-[5-(5,3-difluoro-benzyl)-h1-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino )–benzamide | |
IL237369B (en) | N-]2-(6-fluoro-h1-indol-3-yl)ethyl]-3-(2, 2, 3, 3- tetrafluoropropoxy) benzylamine in combination with an acetylcholinesterase inhibitor for the treatment of Alzheimer's disease | |
MX365939B (es) | Moduladores del transporte nuclear y usos de los mismos. | |
IN2015DN01156A (es) | ||
IN2014DN09434A (es) | ||
PH12016500582A1 (en) | Heterocyclic compounds and uses thereof | |
SG10201808053XA (en) | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders | |
EP4282479A3 (en) | Use of pridopidine to treat depression or anxiety | |
MX2021001169A (es) | Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acético, composiciones, y usos de las mismas. | |
MX2016000364A (es) | Metodos para tratar o prevenir afecciones oftalmologicas. | |
MX2016002794A (es) | Compuestos antiproliferativos. | |
CL2015002897A1 (es) | Inhibidores de bace1 | |
JP2014530840A5 (es) | ||
MX2016008429A (es) | Derivado de piranocromenil fenol, y composicion farmaceutica para tratar un sindrome metabolico o enfermedad inflamatoria. | |
PH12016500140A1 (en) | Heterobicycloaryl rorc2 inhibitors and methods of use thereof | |
CR20110267A (es) | Tratamiento de transtornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il) benzo[]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma | |
EA032271B9 (ru) | Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний | |
WO2012158672A3 (en) | Compounds for use in treatment of mucositis | |
MY173573A (en) | Pyridin-4-yl derivatives | |
MX2014014308A (es) | Pirrolidino heterociclos. | |
MX2015008502A (es) | Sales sulfato de n-(3-(4-(3-(diisobutilamino)propil)piperazin-1-il )propil)-1h-benzo [d]imidazol-2-amina, preparación y uso de las mismas. | |
WO2015066302A3 (en) | Compositions, methods of use, and methods of treatment | |
BR112015004469A2 (pt) | sirna e seu uso em métodos e composições para o tratamento e/ou prevenção de condições oculares | |
MX370061B (es) | Uso de antagonistas del par-1 para prevenir y/o tratar condiciones patologicas funcionales pelviperineales. | |
RS53457B (en) | COMPOSITION AND ITS APPLICATION IN THE TREATMENT OF ANAL RAGAD |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |